Genenta Science, SpA Announces Participation in the D. Boral Capital Inaugural Global Conference

Genenta Science, SpA (NASDAQ: GNTA), a clinical-stage immuno-oncology company, has announced its participation in the D. Boral Capital Inaugural Global Conference, which will take place on May 14, 2025, at The Plaza Hotel in New York City. Carlo Russo, the Chief Medical Officer, will be available for one-on-one meetings during the event from 9:00 A.M. to 3:00 P.M. Eastern Time. Interested parties wishing to schedule a meeting can reach out to John Perez at D. Boral Capital for arrangements.

Genenta Science is focused on developing innovative therapies for solid tumor cancers using its proprietary hematopoietic stem cell technology. Its lead product candidate, Temferon™, aims to facilitate the release of immune-therapeutic agents directly within the tumor microenvironment, which could lead to a more effective and sustained immune response against cancers. The company has completed a Phase 1 trial for newly diagnosed Glioblastoma Multiforme patients, indicating potential for reprogramming the tumor environment to enhance T cell responses and overcome immune tolerance.

In Q4 2024, Genenta initiated a Phase 1/2a study for metastatic Renal Cell Carcinoma, which will explore the efficacy of Temferon™ both as a monotherapy and in combination with immune checkpoint inhibitors. These therapies are intended to be one-time treatments with the possibility of significantly boosting the effectiveness of existing cancer therapies.

D. Boral Capital LLC, the organizer of the conference, is a New York-based investment bank specializing in advisory and financing solutions for emerging growth companies. With a strong presence on Wall Street, D. Boral Capital has successfully secured over $25 billion in capital through numerous transactions across different sectors worldwide.

Genenta Science, SpA (NASDAQ: GNTA) is attracting attention in the oncology sector with its innovative therapeutic approaches, particularly as it prepares to participate in the D. Boral Capital Inaugural Global Conference in New York City on May 14, 2025. This engagement could be pivotal for Genenta, providing an opportunity to showcase its groundbreaking immuno-oncology therapies to a global audience of investors and healthcare professionals.

Genenta’s lead candidate, Temferon™, represents a novel methodology for treating solid tumors by potentially reprogramming the tumor microenvironment. With the completion of a Phase 1 trial for Glioblastoma patients and the recent initiation of a Phase 1/2a study for metastatic Renal Cell Carcinoma, investor interest may heighten in the lead-up to the conference. These studies illustrate Genenta's commitment to understanding and extending the potential of its therapies, particularly in combination with immune checkpoint inhibitors, which could significantly enhance treatment efficacy.

As Genenta aims to capitalize on this momentum, investors should consider several factors. First, the clinical trial results could lead to substantial market valuation changes, given the high unmet needs in the oncology space. Positive interim data may lead to robust buying interest and increased visibility among institutional investors.

However, investors should also remain vigilant regarding the inherent risks of investing in clinical-stage biotech firms. The uncertainty surrounding clinical trial outcomes and regulatory approvals can lead to volatility in the stock price. Therefore, it’s advisable for potential investors to weigh the innovative aspects of Genenta's technology and growth prospects along with their risk tolerance levels.

Overall, Genenta Science appears well-positioned for growth, particularly in light of its upcoming conference participation which may enhance shareholder sentiment and attract further investment.